This comprehensive review aims to explore imaging outcome measures targeting compartmentalized inflammation in Phase 2 clinical trials for multiple sclerosis (MS). The traditional primary imaging outcomes used in Phase 2 MS trials, new or enhancing white matter lesions on MRI, target the effects of peripheral inflammation, but the widespread inflammation behind a mostly closed blood-brain barrier is not captured. This review discusses several emerging imaging technologies that could be used as surrogate markers of compartmentalized inflammation, targeting chronic active lesions, meningeal inflammation, and innate immune activation within the normal-appearing white matter and gray matter. The integration of specific imaging outcomes into Phase 2 trials can provide a more accurate assessment of treatment efficacy, ultimately contributing to the development of more effective therapies for MS.
LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–911.
2.
LublinFDReingoldSCCohenJA, et al. Defining the clinical course of multiple sclerosis. Neurology2014; 83: 278–286.
3.
KapposLBar-OrACreeBAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet2018; 391: 1263–1273.
4.
KuhlmannTMocciaMCoetzeeT, et al. Time for a new mechanism-driven framework to define multiple sclerosis progression. Lancet Neurol2023; 22: 78–88.
5.
HarrisJOFrankJAPatronasN, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history. Annals of Neurology1991; 29: 548–555.
6.
PrineasJWKwonEEChoES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol2001; 50: 646–657.
7.
MagliozziRHowellOVoraA, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain2007; 130: 1089–1104.
AbsintaMSatiPSchindlerM, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest2016; 126: 2597–2609.
10.
MaggiPKuhleJSchädelinS, et al. Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology2021; 97: e543–e553.
11.
LuchettiSFransenNLvan EdenCG, et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol2018; 135: 511–528.
12.
ChomykAKucinskiRKimJ, et al. Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis. Annals of Neurology2024; 95: 907–916.
13.
KeeRNaughtonMMcDonnellGV, et al. A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. Biomedicines2022; 10: 2604.
14.
RealiCMagliozziRRoncaroliF, et al. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol2020; 30: 779–793.
15.
WooMSEnglerJBFrieseMA. The neuropathobiology of multiple sclerosis. Nat Rev Neurosci. Epub ahead of print 24 May 2024. DOI: 10.1038/s41583-024-00823-z.
16.
TsoukiFWilliamsA. Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. Stem Cells2021; 39: 993–1007.
17.
Dal-BiancoAGrabnerGKronnerwetterC, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol2017; 133: 25–42.
18.
AbsintaMSatiPMasuzzoF, et al. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol2019; 76: 1474–1483.
19.
ReevesJAMohebbiMWicksT, et al. Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years. Mult Scler2024; 30: 535–545.
20.
AbsintaMMaricDGharagozlooM, et al. A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis. Nature2021; 597: 709–714.
21.
KaunznerUWKangYZhangS, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain2019; 142: 133–145.
22.
BagnatoFSatiPHemondCC, et al. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain2024; awae013.
23.
SatiPThomassonDMLiN, et al. Rapid, high-resolution, whole-brain, susceptibility-based MRI of multiple sclerosis. Mult Scler2014; 20: 1464–1470.
24.
HemondCCReichDSDundamadappaSK. Paramagnetic Rim Lesions in Multiple Sclerosis: Comparison of Visualization at 1.5-T and 3-T MRI. AJR Am J Roentgenol2022; 219: 120–131.
25.
ClarkeMAParetoDPessini-FerreiraL, et al. Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. AJNR Am J Neuroradiol2020; 41: 1001–1008.
26.
Eskreis-WinklerSDehKGuptaA, et al. Multiple sclerosis lesion geometry in quantitative susceptibility mapping (QSM) and phase imaging. J Magn Reson Imaging2015; 42: 224–229.
27.
StüberCPittDWangY. Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping. Int J Mol Sci2016; 17: 100.
28.
ReevesJAMohebbiMZivadinovR, et al. Reliability of paramagnetic rim lesion classification on quantitative susceptibility mapping (QSM) in people with multiple sclerosis: Single-site experience and systematic review. Mult Scler Relat Disord2023; 79: 104968.
29.
LouCSatiPAbsintaM, et al. Fully automated detection of paramagnetic rims in multiple sclerosis lesions on 3T susceptibility-based MR imaging. Neuroimage Clin2021; 32: 102796.
30.
BarqueroGLa RosaFKebiriH, et al. RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesion assessment in multiple sclerosis. Neuroimage Clin2020; 28: 102412.
31.
ZhangHNguyenTDZhangJ, et al. QSMRim-Net: Imbalance-aware learning for identification of chronic active multiple sclerosis lesions on quantitative susceptibility maps. Neuroimage Clin2022; 34: 102979.
32.
MaggiPBulckeCVPedriniE, et al. B cell depletion therapy does not resolve chronic active multiple sclerosis lesions. EBioMedicine2023; 94: 104701.
33.
ZingerNPonathGSweeneyE, et al. Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions. Neurol Neuroimmunol Neuroinflamm2022; 9: e1138.
34.
ElliottCWolinskyJSHauserSL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler2019; 25: 1915–1925.
35.
CalviAClarkeMAPradosF, et al. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult Scler2023; 29: 352–362.
36.
ElliottCRudkoDAArnoldDL, et al. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler2023; 29: 680–690.
37.
ArnoldDLElliottCMartinEC, et al. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial. Neurology2024; 102: e208058.
38.
MontalbanXVermerschPArnoldDL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol2024; S1474-4422(24)00328–4.
39.
NakamuraKThoomukuntlaBBenaJ, et al. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis. Mult Scler2024; 30: 369–380.
40.
FoxRJRaskaPBarroC, et al. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Mult Scler2021; 27: 2014–2022.
41.
ZhangLHuKShaoT, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharm Sin B2021; 11: 373–393.
42.
VowinckelEReutensDBecherB, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res1997; 50: 345–353.
43.
NylundMSucksdorffMMatilainenM, et al. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. Brain Commun2022; 4: fcab301.
44.
PolvinenEMatilainenMNylundM, et al. TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm2023; 10: e200133.
45.
HamzaouiMGarciaJBoffaG, et al. Positron Emission Tomography with [F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression. Annals of Neurology2023; 94: 366–383.
46.
De PickerLJMorrensMBranchiI, et al. TSPO PET brain inflammation imaging: A transdiagnostic systematic review and meta-analysis of 156 case-control studies. Brain Behav Immun2023; 113: 415–431.
47.
AbsintaMVuoloLRaoA, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology2015; 85: 18–28.
48.
OkarSVDieckhausHBeckES, et al. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis. Invest Radiol2024; 59: 243–251.
49.
AhmedSMFransenNLTouilH, et al. Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive multiple sclerosis. JCI Insight2022; 7: e151683.
50.
BhargavaPWickenCSmithMD, et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Mult Scler Relat Disord2019; 30: 136–140.
51.
Lucchinetti ClaudiaF.Popescu BogdanF.G.Bunyan ReemF., et al. Inflammatory Cortical Demyelination in Early Multiple Sclerosis. New England Journal of Medicine2011; 365: 2188–2197.
52.
MaineroCBennerTRaddingA, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology2009; 73: 941–948.
53.
BeckESGaiNFilippiniS, et al. Inversion Recovery Susceptibility Weighted Imaging With Enhanced T2 Weighting at 3 T Improves Visualization of Subpial Cortical Multiple Sclerosis Lesions. Invest Radiol2020; 55: 727–735.
54.
SatiP. Diagnosis of multiple sclerosis through the lens of ultra-high-field MRI. J Magn Reson2018; 291: 101–109.
55.
BeckESMaranzanoJLucianoNJ, et al. Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis. Mult Scler2022; 28: 1351–1363.
56.
TreabaCAGranbergTESormaniMP, et al. Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI. Radiology2019; 291: 740–749.
57.
HerranzETreabaCABarlettaVT, et al. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain2024; awae030.
58.
HealyLMStrattonJAKuhlmannT, et al. The role of glial cells in multiple sclerosis disease progression. Nat Rev Neurol2022; 18: 237–248.
59.
HerranzEGiannìCLouapreC, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol2016; 80: 776–790.
60.
HarrisonDMChoiSBakshiR, et al. Pooled analysis of multiple sclerosis findings on multisite 7 Tesla MRI: Protocol and initial observations. Hum Brain Mapp2024; 45: e26816.
61.
GillenKMMubarakMParkC, et al. QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions. Ann Clin Transl Neurol2021; 8: 877–886.
62.
BagnatoFHametnerSYaoB, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain2011; 134: 3602–3615.
63.
KolbHAbsintaMBeckES, et al. 7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions. Ann Neurol2021; 90: 612–626.
64.
RahmanzadehRGalbuseraRLuP-J, et al. A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis. Ann Neurol2022; 92: 486–502.
65.
CagolABenkertPMelie-GarciaL, et al. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. Neurology2024; 102: e207768.
66.
ElliottCArnoldDLChenH, et al. Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. AJNR Am J Neuroradiol2020; 41: 1584–1591.
ElliottCBelachewSWolinskyJS, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019; 142: 2787–2799.
69.
HarrisonDMWangKYFiolJ, et al. Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume. J Neuroimaging2017; 27: 461–468.
70.
VercellinoMCostantiniGCogoniM, et al. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study. Mult Scler2023; 29: 1526–1539.
71.
BoumanPMSteenwijkMDPouwelsPJW, et al. Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. Brain2020; 143: 2988–2997.
72.
KilsdonkIDJonkmanLEKlaverR, et al. Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain2016; 139: 1472–1481.
73.
SucksdorffMMatilainenMTuiskuJ, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain2020; 143: 3318–3330.
